CVE:DMA - DiaMedica Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.65 -0.05 (-7.14 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseC$0.65
Today's RangeC$0.63 - C$0.70
52-Week RangeC$0.21 - C$0.90
Volume633,900 shs
Average Volume201,520 shs
Market CapitalizationC$48.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMA News and Ratings via Email

Sign-up to receive the latest news and ratings for DMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange CVE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolCVE:DMA
CUSIPN/A
Phone+1-763-4965454

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-1,025.50%
Return on Assets-241.18%

Miscellaneous

EmployeesN/A
Outstanding Shares156,425,000
Market CapC$48.84

DiaMedica Therapeutics (CVE:DMA) Frequently Asked Questions

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "DMA."

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc (CVE:DMA) posted its quarterly earnings results on Wednesday, May, 30th. The company reported ($0.01) earnings per share (EPS) for the quarter. View DiaMedica Therapeutics' Earnings History.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, September, 4th 2018. View Earnings Estimates for DiaMedica Therapeutics.

What is the consensus analysts' recommendation for DiaMedica Therapeutics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of DiaMedica Therapeutics' key competitors?

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the folowing people:
  • Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
  • Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
  • Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
  • Dr. Dennis D. Kim, Consulting Chief Medical Officer (Age 48)

Has DiaMedica Therapeutics been receiving favorable news coverage?

News coverage about DMA stock has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DiaMedica Therapeutics earned a news sentiment score of 0.10 on Accern's scale. They also gave media coverage about the company an impact score of 45.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMA stock can currently be purchased for approximately C$0.65.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of C$48.84 million.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Pkwy N # N165, MINNEAPOLIS, MN 55447-4466, United States. The company can be reached via phone at +1-763-4965454.


MarketBeat Community Rating for DiaMedica Therapeutics (CVE DMA)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.